Table 5 Properties of approved small-molecule inhibitors of BCL-2, hedgehog pathway, proteasome, and PARP
From: Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Chemical structure | Name | Targets | Approved indications (year) | Corporation |
|---|---|---|---|---|
| Venetoclax (Venclyxto) | BCL-2 | CLL (2016) SLL (2018) AML (2018) | Abbvie/Genentech |
| Vismodegib (Erivedge) | SMO | BCC (2012) | Genentech |
| Sonidegib (Odomzo) | SMO | BCC (2015) | Novartis |
| Glasdegib (Daurismo) | SMO | AML (2018) | Pfizer |
| Bortezomib (Velcade) | Proteasome | MM (2003) MCL (2006) | Millennium |
| Carfilzomib (Kyprolis) | Proteasome | MM (2012) | Onyx |
| Ixazomib (Ninlaro) | Proteasome | MM (2015) | Takeda |
| Olaparib (Lynparza) | PARP1/2/3 | Ovarian cancer (2014) FTC (2015) Breast cancer (2018) Pancreatic adenocarcinoma (2019) Prostate cancer (2020) | AstraZeneca |
| Rucaparib (Rubraca) | PARP1/2/3 | Ovarian cancer (2016) FTC (2016) PPC (2018) Prostate cancer (2020) | Clovis |
| Niraparib (Zejula) | PARP1/2 | Ovarian cancer (2017) FTC (2017) PPC (2017) | Tesaro/Takeda/Janssen |
| Talazoparib (Talzenna) | PARP1/2 | Breast cancer (2018) | Pfizer |
